Alliance Global Partners analyst James Molloy raised the firm’s price target on Akari Therapeutics (AKTX) to $7 from $4 and keeps a Buy rating on the shares. The firm cites its expectations for the company’s new antibody drug conjugate centered pipeline following its 2024 merger with Peak Bio for the target increase.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKTX: